These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9314645)

  • 1. No effect of unfractioned or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy.
    Myrup B; Jensen T; Gram J; Kluft C; Jespersen J; Deckert T
    Diabetes Care; 1997 Oct; 20(10):1615-9. PubMed ID: 9314645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy.
    Myrup B; Rossing P; Jensen T; Parving HH; Hølmer G; Gram J; Kluft C; Jespersen J
    Scand J Clin Lab Invest; 2001; 61(5):349-56. PubMed ID: 11569481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological inhibitors of blood coagulation and prothrombin fragment F 1 + 2 in type 2 diabetic patients with normoalbuminuria and incipient nephropathy.
    Mormile A; Veglio M; Gruden G; Girotto M; Rossetto P; D'Este P; Cavallo-Perin P
    Acta Diabetol; 1996 Sep; 33(3):241-5. PubMed ID: 8904933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
    Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S
    Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcapillary escape rate and albuminuria in Type II diabetes. Effects of short-term treatment with low-molecular weight heparin.
    Nielsen S; Schmitz A; Bacher T; Rehling M; Ingerslev J; Mogensen CE
    Diabetologia; 1999 Jan; 42(1):60-7. PubMed ID: 10027580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty.
    Tschopl M; Tsakiris DA; Marbet GA; Labs KH; Jäger K
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3208-14. PubMed ID: 9409313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study.
    Greaves M; Malia RG; Goodfellow K; Mattock M; Stevens LK; Stephenson JM; Fuller JH
    Diabetologia; 1997 Jun; 40(6):698-705. PubMed ID: 9222650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
    Sartorio A; Cattaneo M; Bucciarelli P; Bottasso B; Porretti S; Epaminonda P; Faglia G; Arosio M
    Exp Clin Endocrinol Diabetes; 2000; 108(7):486-92. PubMed ID: 11083070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy.
    Tarnow L; Rossing P; Nielsen FS; Hansen BV; Dyerberg J; Parving HH
    Diabetes Care; 1996 Dec; 19(12):1382-7. PubMed ID: 8941468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fish oil in diabetic nephropathy.
    Rossing P; Hansen BV; Nielsen FS; Myrup B; Hølmer G; Parving HH
    Diabetes Care; 1996 Nov; 19(11):1214-9. PubMed ID: 8908382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population.
    Welty FK; Mittleman MA; Wilson PW; Sutherland PA; Matheney TH; Lipinska I; Muller JE; Levy D; Tofler GH
    Circulation; 1997 Feb; 95(4):825-30. PubMed ID: 9054738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women.
    Rios DR; Rodrigues ET; Cardoso AP; Montes MB; Franceschini SA; Toloi MR
    Nutrition; 2008 Feb; 24(2):120-6. PubMed ID: 18065202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy.
    Yokoyama H; Myrup B; Rossing P; Ostergaard PB
    Diabetes Care; 1996 May; 19(5):441-5. PubMed ID: 8732706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy.
    Zimmermann J; Schramm L; Wanner C; Mulzer E; Henrich HA; Langer R; Heidbreder E
    Clin Nephrol; 1996 Oct; 46(4):230-6. PubMed ID: 8905207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia.
    Wada H; Mori Y; Kaneko T; Wakita Y; Nakase T; Minamikawa K; Ohiwa M; Tamaki S; Tanigawa M; Kageyama S
    Am J Hematol; 1993 Oct; 44(2):112-6. PubMed ID: 8266915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy.
    Asakawa H; Tokunaga K; Kawakami F
    J Diabetes Complications; 2000; 14(3):121-6. PubMed ID: 10989319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A; Bayraktar M; Kirazli S
    Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand factor and development of diabetic nephropathy in IDDM.
    Stehouwer CD; Stroes ES; Hackeng WH; Mulder PG; Den Ottolander GJ
    Diabetes; 1991 Aug; 40(8):971-6. PubMed ID: 1907250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A trial of the use of the low-molecular heparin sulodexide in the therapy of diabetic nephropathy].
    Zalevskaia AG; Astamirova KhS; Karpova IA; Popova SG
    Ter Arkh; 1998; 70(3):71-4. PubMed ID: 9575594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.